There are currently 794 clinical trials in Detroit, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Henry Ford Hospital, Henry Ford Health System, Barbara Ann Karmanos Cancer Institute and Wayne State University/Karmanos Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
NCT05266001
Recruiting
The GRACE-2 study is a prospective, multi-center, double-blind, randomized controlled trial of the drug GM-CSF vs placebo in children with sepsis-induced multiple organ dysfunction syndrome (MODS) who have immunoparalysis with mild to moderate inflammation.
Gender:
All
Ages:
Between 1 day and 17 years
Trial Updated:
02/07/2023
Locations: Children's Hospital of Michigan, Detroit, Michigan
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
Register for Updates
A Study of ZN-c3 in Participants With Solid Tumors
NCT04158336
Recruiting
This is a Phase 1 open-label, multicenter study of ZN-c3 monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2023
Locations: Site 0101, Detroit, Michigan
Conditions: Solid Tumor
Register for Updates
Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders
NCT03941366
Recruiting
The current standard of care for rectal cancer has diminished local recurrence and enhanced survival. Quality of life, however, remains poor for many patients and the probability of distant recurrence is high. In this study, we will attempt to reduce the distant recurrence rate and improve quality of life by making changes in the timing and administration of chemotherapy and radiation and doing less invasive rectal surgery when indicated.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
01/30/2023
Locations: Ascension St. John Hospital, Detroit, Michigan
Conditions: Rectal Cancer
Register for Updates
Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis
NCT04316442
Recruiting
The STI-6129-001 study is a three-stage, multicenter, open-label, dose-finding, phase 1b/2a trial. It is designed primarily to identify the recommended phase 2 dose (RP2D) of STI-6129 by assessing the safety, preliminary efficacy and pharmacokinetics of this anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC) for the treatment of relapsed or refractory systemic AL amyloidosis. The patients that will be treated with STI-6129 in this trial are relapsed or refractory systemic AL amyloidosis pati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: Barbara Ann Karmanos Cancer Institute Wertz Clinic, Detroit, Michigan
Conditions: Light Chain (AL) Amyloidosis
Register for Updates
HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer
NCT04188951
Recruiting
The study is a pilot study to explore the feasibility and efficacy of immunotherapy following salvage surgery for recurrent head and neck cancer.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
12/19/2022
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Head and Neck Neoplasms
Register for Updates
Pressure-Volume Loop During High-Risk PCI
NCT04681313
Recruiting
This study will examine the physiologic effects on loading conditions and contractility of the left ventricle during high-risk primary coronary intervention (HRPCI) in the Cardiac Cath Lab. This will be performed through analysis of real-time left ventricular (LV) pressure-volume loops (PVL) by continuously recording PVL during HRPCI with the Inca® Pressure-Volume Loop System that will be temporarily placed in the left ventricle during the procedure.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/06/2022
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Coronary Artery Disease
Register for Updates
MEASuRE: Metreleptin Effectiveness And Safety Registry
NCT02325674
Recruiting
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
Gender:
All
Ages:
All
Trial Updated:
11/23/2022
Locations: Detroit Children's Hospital, Detroit, Michigan
Conditions: Generalised Lipodystrophy, Partial Lipodystrophy
Register for Updates
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Ascension Saint John Hospital, Detroit, Michigan
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: Henry Ford Cancer Institute, Detroit, Michigan
Conditions: Leukemia, Myeloid, Acute
Register for Updates
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
NCT05569057
Recruiting
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/03/2022
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Breast Cancer
Register for Updates
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804
Recruiting
To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/28/2022
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Register for Updates